Influence of Molecular Abnormalities on Treatment Response of Venetoclax Plus Azacytidine and Homoharringtonine Versus Venetoclax Plus Hypomethylating Agent in Relapsed/Refractory Acute Myeloid Leukemia

被引：3
|
作者：
Yu, Guopan [1 ]
Yin, Zhao [1 ]
Jin, Hua [1 ]
Yu, Sijian [1 ]
Li, Yuhua [2 ]
Nie, Danian [3 ]
Guo, Ziwen [4 ]
Sun, Zhiqiang [5 ]
Meng, Qingxiang [6 ]
Zhao, Weihua [7 ]
Lin, Dongjun [8 ]
Xu, Na [1 ]
Zhang, Yu [1 ]
机构：
[1] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Peoples R China
[2] Southern Med Univ, Zhujiang Hosp, Dept Hematol, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Hematol, Guangzhou, Peoples R China
[4] Zhongshan City Peoples Hosp, Dept Hematol, Zhongshan, Peoples R China
[5] Southern Med Univ, Shenzhen Hosp, Dept Hematol, Shenzhen, Peoples R China
[6] Peking Univ, Shenzhen Hosp, Shenzhen, Peoples R China
[7] Guangxi Med Univ, Affiliated Hosp 1, Nanning, Peoples R China
[8] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Hematol, Shenzhen, Peoples R China
来源：
BLOOD | 2022年 / 140卷
关键词：
relapsed/refractory acute myeloid leukemia; venetoclax; HHT; molecular mutation; cytogenetic abnormalities;
D O I：
10.1182/blood-2022-168004
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
617
引用
收藏
页码：11796 / 11796
页数：1
相关论文
共 50 条
  • [1] Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent
    Steinauer, Nickolas
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede H.
    Mangaonkar, Abhishek A.
    Saliba, Antoine N.
    Torghabeh, Mehrdad
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun
    Patnaik, Mrinal M.
    Pardanani, Animesh
    Badar, Talha
    Murthy, Hemant
    Foran, James
    Yi, Cecilia Arana
    Tefferi, Ayalew
    Gangat, Naseema
    HAEMATOLOGICA, 2024, 109 (08) : 2706 - 2710
  • [2] Venetoclax plus Cladribine plus Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax plus Hypomethylating Agent
    Steinauer, Nickolas
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan
    Begna, Kebede
    Mangaonkar, Abhishek A.
    Saliba, Antoine
    Hefazi, Mehrdad
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun V.
    Pardanani, Animesh D.
    Badar, Talha
    Murthy, Hemant S.
    Foran, James M.
    Yi, Cecilia Y. Arana
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD, 2023, 142
  • [3] Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
    Johnson, Isla McKerrow
    Ilyas, Rimal
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede
    Mangaonkar, Abhishek A.
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun, V
    Patnaik, Mrinal M.
    Pardanani, Animesh
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD, 2022, 140 : 3233 - 3234
  • [4] Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naive acute myeloid leukemia
    Gangat, Naseema
    Johnson, Isla
    McCullough, Kristen
    Farrukh, Faiqa
    Al-Kali, Aref
    Alkhateeb, Hassan
    Begna, Kebede
    Mangaonkar, Abhishek
    Litzow, Mark
    Hogan, William
    Shah, Mithun
    Patnaik, Mrinal
    Pardanani, Animesh
    Tefferi, Ayalew
    HAEMATOLOGICA, 2022, 107 (10) : 2501 - 2505
  • [5] Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia
    Weng, Guangyang
    Zhang, Yu
    Yu, Guopan
    Luo, Tingyue
    Yu, Sijian
    Xu, Na
    Sun, Zhiqiang
    Lin, Dongjun
    Deng, Lan
    Liang, Xinquan
    Xiao, Jie
    Zhang, Hongyu
    Guo, Ziwen
    Shao, Ruoyang
    Du, Xin
    Jin, Hua
    Liu, Qifa
    JOURNAL OF INTERNAL MEDICINE, 2023, 293 (03) : 329 - 339
  • [6] Association of Genetic Characteristics with Response to Venetoclax Plus Hypomethylating Agents in Relapsed and Refractory Acute Myeloid Leukemia
    Weng, Guangyang
    Zhang, Yu
    Yu, Guopan
    Xu, Na
    Sun, Zhiqiang
    Lin, Dongjun
    Liang, Xinquan
    Deng, Lan
    Xiao, Jie
    Zhang, Hongyu
    Guo, Ziwen
    Jin, Hua
    Du, Xin
    Liu, Qifa
    BLOOD, 2022, 140 : 2025 - 2026
  • [7] Hypomethylating Agent/Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia
    Jamy, Omer Hassan
    Worth, Sarah
    Rangaraju, Sravanti
    Bachiashvili, Kimo
    Vachhani, Pankit
    Bhatia, Ravi
    BLOOD, 2021, 138
  • [8] Outcomes of Adults Treated with a Hypomethylating Agent Plus Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia: A Multicenter Retrospective Study
    Geramita, Emily
    Wang, Hong
    Bastacky, Melissa
    Cohen, Jessica
    Shallis, Rory Michael
    Badar, Talha
    Litzow, Mark R.
    Im, Annie
    BLOOD, 2022, 140 : 6187 - 6188
  • [9] Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax
    Asghari, Hannah
    Lee, Dasom
    Deutsch, Yehuda E.
    Chan, Onyee
    Al Ali, Najla
    Boisclair, Stephanie
    Brahim, Amanda
    Padron, Eric
    Kuykendall, Andrew T.
    List, Alan F.
    Fernandez, Hugo F.
    Lancet, Jeffrey E.
    Sallman, David A.
    Komrokji, Rami S.
    Sweet, Kendra L.
    Talati, Chetasi
    BLOOD, 2019, 134
  • [10] Venetoclax Plus Hypomethylating Agents for Relapsed/Refractory Acute Myeloid Leukemia (AML) Is Safe and Manageable in the Outpatient Setting
    Nanni, Jacopo
    Papayannidis, Cristina
    Cristiano, Gianluca
    Marconi, Giovanni
    Sartor, Chiara
    Parisi, Sarah
    Ottaviani, Emanuela
    Baldini, Lorenza
    Testoni, Nicoletta
    Baldazzi, Carmen
    Ricci, Paolo
    Bezzi, Chiara Di Giovanni
    Abd-alatif, Rania
    Paolini, Stefania
    Cavo, Michele
    Curti, Antonio
    BLOOD, 2020, 136
12345